Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,552,405
  • Shares Outstanding, K 117,597
  • Annual Sales, $ 1,015 M
  • Annual Income, $ 444,090 K
  • EBIT $ 808 M
  • EBITDA $ 886 M
  • 60-Month Beta 0.97
  • Price/Sales 8.13
  • Price/Cash Flow 16.86
  • Price/Book 18.30

Options Overview Details

View History
  • Implied Volatility 36.45% (-4.46%)
  • Historical Volatility 32.51%
  • IV Percentile 35%
  • IV Rank 23.71%
  • IV High 59.09% on 04/04/25
  • IV Low 29.41% on 06/16/25
  • Expected Move (DTE 10) 4.06 (5.05%)
  • Put/Call Vol Ratio 0.62
  • Today's Volume 992
  • Volume Avg (30-Day) 575
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 12,490
  • Open Int (30-Day) 12,772
  • Expected Range 76.42 to 84.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.07
  • Number of Estimates 4
  • High Estimate 2.14
  • Low Estimate 1.86
  • Prior Year 1.19
  • Growth Rate Est. (year over year) +73.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.85 +16.89%
on 01/26/26
82.22 -2.12%
on 02/09/26
+8.01 (+11.05%)
since 01/09/26
3-Month
61.22 +31.45%
on 12/11/25
82.22 -2.12%
on 02/09/26
+12.24 (+17.94%)
since 11/07/25
52-Week
47.50 +69.43%
on 05/14/25
82.22 -2.12%
on 02/09/26
+23.38 (+40.95%)
since 02/07/25

Most Recent Stories

More News
3 Small-Cap Stocks with Solid Fundamentals

3 Small-Cap Stocks with Solid Fundamentals

AWI : 199.86 (+0.81%)
HALO : 80.48 (-0.92%)
WBTN : 11.39 (+1.97%)
3 Growth Stocks Set to Flourish

3 Growth Stocks Set to Flourish

ARES : 137.25 (+5.20%)
VRT : 202.00 (+3.28%)
HALO : 80.48 (-0.92%)
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Updates Preliminary Unaudited 2025 Estimates: - Total Revenue of  $1,385 - $1,400 million, YoY Growth of 36% to 38% 1 - Royalty Revenue of $865 - $870...

HALO : 80.48 (-0.92%)
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

SAN DIEGO , Jan. 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30...

HALO : 80.48 (-0.92%)
Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks

Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks

HALO : 80.48 (-0.92%)
1 Surging Stock Worth Investigating and 2 We Brush Off

1 Surging Stock Worth Investigating and 2 We Brush Off

MBLY : 9.07 (+4.13%)
SATS : 115.19 (+3.21%)
HALO : 80.48 (-0.92%)
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Agreement provides Takeda with exclusive access to ENHANZE ® drug delivery technology for vedolizumab

HALO : 80.48 (-0.92%)
Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings?

Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings?

HALO : 80.48 (-0.92%)
Targeted Precision: Rare Disease Assets Attract Record Regulatory Momentum

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market...

ONCY : 0.8633 (-2.55%)
IDYA : 32.39 (+0.68%)
ZLAB : 18.44 (+2.44%)
CHRS : 2.06 (-3.74%)
HALO : 80.48 (-0.92%)
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab

SKYE : 0.7773 (-5.13%)
HALO : 80.48 (-0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 83.47
2nd Resistance Point 82.85
1st Resistance Point 81.66
Last Price 80.48
1st Support Level 79.85
2nd Support Level 79.23
3rd Support Level 78.04

See More

52-Week High 82.22
Last Price 80.48
Fibonacci 61.8% 68.96
Fibonacci 50% 64.86
Fibonacci 38.2% 60.76
52-Week Low 47.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar